


# Financial highlights

## Revenue / Core operating profit




**Revenue:** Revenue rose 8.0% year on year because of an increase in sales of products launched in fiscal 2022 or later and cost pass-throughs, particularly for low-priced drugs.

**Core operating profit:** Core operating profit rose 11.7% year on year as a result of increased revenue and revised distribution pricing policy despite greater costs.


Note: Fiscal 2022 and fiscal 2023 figures are for continuing businesses, excluding discontinued business

## R&D expenses




The Sawai Group continued to invest aggressively in research and development in order to be first to market with new products that will differentiate us from our competitors to achieve future growth.

## Profit attributable to owners of the Company / Return on equity attributable to owners of the Company



Both operating profit and profit attributable to owners of the Company rose as a result of increased revenue from the Japan business and our efforts to maintain our cost ratio due to pricing policies. Contributions to profit from the discontinued US business were about the same as those for the previous fiscal year.


## Dividends per share / Dividend on equity ratio



In the new Medium-Term Business Plan announced in June 2024, we set forth the policy of providing stable and continuous dividends, taking into account overall medium- to long-term profit levels, DOE, etc. In fiscal 2023, the Company provided an annual return to shareholders of ¥130 per share.


# Non-financial highlights (Scope of data: Sawai Pharmaceutical)

## Sales volume / Production capacity




The Group's ability to supply a relatively large number of top quality generic drugs is backed by our industry-leading production capacity. Production capacity increased 3.0 billion tablets year on year as Trust Pharmatech started operations.

## Amount of medical cost-saving impact



The Sawai Group's greatest contribution to society lies in increasing the sustainability of the health insurance system by reducing the burden of medical expenses through the supply of generic drugs. While the difference between the price of long-listed drugs whose patents have expired and that of generic drugs is shrinking, our generic drugs contributed to healthcare cost savings of about ¥290.0 billion, which still substantially exceeds our revenue.

## Number of GMP audits



Sawai Pharmaceutical has formed a dedicated audit team, which performs more than 100 GMP audits a year on average. The number of audits conducted each fiscal year fluctuates within a certain range, as the year for the next audit is determined based on the results of the previous audit. As the number of products manufactured and marketed grows, the number of audits at new manufacturing sites has increased annually, and remote audits and commissioned audits by independent parties have been used to cover the increase.

## CO<sub>2</sub> emissions



Despite our having started to purchase non-fossil CO<sub>2</sub>-free electricity in fiscal 2023, there has been an upward trend for various reasons, including increased operating rates at Group offices.